Gene variations and cancer risk – more results, more answers and more questions

Reseacher looking at DNA fingerprint

Scientists have found around eighty new gene variations linked to breast, prostate and ovarian cancers

A thousand scientists from one hundred international research groups working over four years. Thirteen papers spread across five journals. DNA analysis of two hundred thousand people. And eighty new genetic variations, or SNPs (pronounced “snips”) linked to three different types of cancer, doubling the current total known about so far.

These are impressive, big figures from an equally impressive, big piece of science, which Cancer Research UK helped to fund (here’s the press release). But what does it all mean?

To find out, we spoke to Professor Doug Easton from the University of Cambridge, one of the leaders of the project.

Cancer Research UK: What exactly are SNPs?

Prof Easton: SNP stands for “single nucleotide polymorphism”, and it’s a single ‘letter’ difference in the DNA between individuals. Your DNA is made up of around 3 billion of these ‘letters’ – there are four possible letters you can have: A, C, T and G – so a SNP is just a single place in your genome where you might have one particular letter, and someone else has a different one.

To explain a bit more about SNPs and what they do, have a look at this short animation:

Continue reading

On the origin of tumours

Darwin's first sketch of an evolutionary tree, from 1837

Researchers now think tumours evolve in a Darwinian fashion

“Cancer starts when a single cell in our body starts dividing out of control.”

We repeat this statement so often it would be banal, were it not for its implications.

But after a single, initial, malignant cell division, what happens to the two resulting ‘daughter’ cells? Are they identical to their parents? And what about their daughters? And their daughters’ daughters?

And what about the offspring that split off and travel around the body? After all, it’s usually cancer’s tendency to spread that makes it dangerous, rather than the initial tumour itself. But why is it that advanced cancer is so hard to treat?

Today, a team of some of the UK’s most exciting young researchers, funded by Cancer Research UK, University College London Cancer Institute, the Medical Research Council and the Wellcome Trust, has published results of a three-year analysis of kidney cancer samples.

Sequencing billions of ‘letters’ of DNA, the researchers looked in unprecedented detail at the relatedness of different regions of patients’ tumours, and between the patients’ primary tumour and the more distant secondaries, or ‘metastases’.

Their findings are stark: whichever way they looked at the data, no two samples from the same patient were genetically identical – not even samples next to each other in the original tumour. And the secondaries were significantly different from their parent tumour.

Their findings are the most compelling evidence yet that, like populations of animals in an ecosystem, tumours adapt as they grow, obeying the fundamental evolutionary laws laid down by Charles Darwin over a century ago. It seems this evolutionary aptitude may foster their ability to spread, and to become resistant to almost every treatment we can throw at them.

This heterogeneous nature of cancer has big implications for the way we think about the disease, and for how we continue to improve the way we treat it.

Continue reading

You could pay to find out about your cancer risk – but you might not get what you bargained for

Researcher looking at DNA

At the moment, direct-to-consumer cancer tests aren't ready for widespread public use.

New developments in genetic research and medical scanning are promising to usher us into a world of personalised health care. Several businesses now offer ‘direct-to-consumer’ gene tests, implying that they can tell healthy people about their risks of developing common diseases, including cancer.  Others advertise ‘health MOTs’ – a full body scan claiming to find early signs of such diseases.

These tests might sound tempting, but ‘personalised’ commercial cancer tests are new territory – and they raise tricky questions about consumer choice, personal responsibility towards healthcare and what role, if any, the Government should be playing in regulating it all.

The Nuffield Council on Bioethics recently launched their new report on ‘personalised medicine’. We went along to the launch event to find out what the experts think of this supposed healthcare revolution. But their basic message was a cautious one, as we shall see…

Continue reading

Scientists inch closer to personal risk prediction – for some

Our genes and our lifestyles can influence our chance of developing cancer

A person’s risk of developing cancer at some point in their life depends on many things, the most obvious of which are their age, their lifestyle and their genes.

So the question many researchers are asking is whether it’s possible to unpick this complex web of influences and accurately predict a person’s cancer risk.

Currently the answer to this challenging question is ‘no’ – at least for most of us.  But – never ones to be daunted by a challenge – some researchers are trying to combine our ever-growing knowledge of the genetic differences between individuals, with a person’s age and life history, to try to predict their cancer risk.

Their goal is to identify people with a high risk of cancer, and to offer them tailored screening, monitoring or lifestyle advice.

Dr Antonis Antoniou, at the University of Cambridge, is one of these researchers. A trained statistician, he is currently developing computer programmes to help doctors to assess a person’s risk of developing certain cancers, based on information about their genetics and family background.

Continue reading

Behind the Headlines: SNPs – hunting for cancer genes

A researcher looking at genetic information

Cancer Research UK has invested in gene-hunting technology

Our genes form the instructions that tell our cells what to do – when to grow, divide and die. These instructions are encoded in the form of DNA. The DNA code is made up of four “letters”, known as A, G, C and T.

Although most of our genes are similar from person to person, there are small variations within them. It is this variation that makes us unique. But over the last decade or two, researchers have been finding that small variations in certain genes also seem to be linked to an increase or decrease in a person’s cancer risk.

At the moment, we only know about relatively few of these genetic variations that are linked to cancer risk. In order to understand more about how our genetic makeup influences our risk, it’s clear that we need to find more. So how do we do it?

Continue reading

Genetic tests for cancer?

A researcher looking at genetic information

Genetic tests - good or bad idea?

In recent years more and more companies have started selling genetic tests to the public directly from the web. In some places genetic testing has even become a social activity.

But are these tests a good idea? And what does this mean for preventing and treating diseases such as cancer?

Continue reading

Decode Genetics breast cancer risk test – our view

Today Icelandic biotech firm Decode Genetics announced the launch of the first commercially available test to assess a woman’s genetic risk of breast cancer, costing around £1,000.

Although we’re rapidly understanding more and more about the role of genes in cancer risk, we believe that it’s too early for a test of this kind to be released to the general public.  We are also concerned that the tests would be used without clear counselling about what the results might mean.

Click on the player below to listen to a short interview with Cancer Research UK Senior Clinical Research Fellow and breast cancer genetics expert, Dr Paul Pharoah, explaining his concerns about the test.

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Link to download (1.4Mb, 2 mins 25)

There’s also an excellent, in-depth exploration of the issue over on Dr Len’s Cancer blog from the American Cancer Society.

Kat